Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 CAEL-101 plus plasma cell dyscrasia treatment in treatment‑naive Mayo stage IIIb AL amyloidosis
jRCT2031200299Phase 3Active, not recruiting
- Sponsor
- Caelum Biosciences
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing CAEL-101 + CyBorD with Placebo + CyBorD (2 arms). Primary endpoints: Overall survival and Safety and tolerability of CAEL-101. Started Jan 2021; status: active, not recruiting.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on jRCT2031200299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200299.